Cita APA

Palazón-Carrión, N., Salar, A., & de la Cruz-Merino, L. (2022). Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-Cell lymphoma: Final results of the R2-GDP-GOTEL trial and immune biomarker subanalysis.

Citación estilo Chicago

Palazón-Carrión, Natalia, Antonio Salar, y L. de la Cruz-Merino. Lenalidomide Plus R-GDP (R2-GDP) in Relapsed/refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. 2022.

Cita MLA

Palazón-Carrión, Natalia, Antonio Salar, y L. de la Cruz-Merino. Lenalidomide Plus R-GDP (R2-GDP) in Relapsed/refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. 2022.